News ArticleVijaya Diagnostic Centre Posts 26.7% Revenue Growth in Q2 FY2027 With Expansion and Acquisition Moves
Company achieves Rs 2,553.9 million revenue supported by 16.5% test volume rise and enters North-East India with Arya Wellness acquisition
Vijaya Diagnostic Centre Limited announced its Q2 FY2027 consolidated financial results, showing a 26.7% year-on-year revenue increase to Rs 2,553.9 million driven by a 16.5% rise in test volumes and continued expansion of diagnostic centers. The company also revealed acquisitions and plans to open additional hubs and spokes to strengthen its presence across India.
Vijaya Diagnostic Centre Limited
General / Other
Vijaya Diagnostic Centre Limited reported a strong performance in Q2 FY2027, with revenues growing 26.7% year-over-year to Rs 2,553.9 million, supported by a 16.5% increase in total diagnostic tests and strategic network expansion including a new acquisition in the Northeast region of India.
Total tests conducted during Q2 FY2027 were 4.98 million, up 16.5% compared to 4.28 million in Q2 FY2026. Total footfall increased 14.5% to 1.37 million, while average realization per test rose 8.8% to Rs 513.
EBITDA for Q2 FY2027 reached Rs 1,127.5 million, a 37.8% increase year-on-year, with the EBITDA margin expanding by 355 basis points to 44.1%. Profit after tax grew 37.4% to Rs 594.7 million, with PAT margin improving to 23.3%.
The company commissioned 2 hubs and 7 spokes during the first half of FY2027 and plans to commission an additional 3 hubs and 7 spokes in the second half, plus 3 more hubs in Q1 FY2028 to expand its diagnostic network.
Vijaya Diagnostic Centre entered into a Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati, marking its entry into the North-East region, aimed at expanding its geographic footprint beyond existing markets.
Highlights
- Revenue from operations increased by 26.7% year-over-year to Rs 2,553.9 million in Q2 FY2027.
- Total diagnostic tests rose 16.5% year-over-year to 4.98 million in Q2 FY2027.
- EBITDA margin improved by 355 basis points to 44.1% in Q2 FY2027.
- Commissioned 2 hubs and 7 spokes so far in FY2027 with plans for further expansion.
- Acquired Arya Wellness Centre in Guwahati, entering the North-East market.
Key Data Snapshot
Financial performance
- Q2 FY2027 revenue increased by 26.7% to Rs 2,553.9 million from Rs 2,015.6 million in Q2 FY2026.
- EBITDA rose 37.8% to Rs 1,127.5 million with margin expanding to 44.1%.
- Profit after tax for the quarter was Rs 594.7 million, a 37.4% rise compared to the prior year.
- Half year revenue grew 24.8% to Rs 4,863.7 million with consistent margin improvements.
Operational performance
- Total diagnostic tests conducted rose 16.5% year-on-year to 4.98 million tests in Q2 FY2027.
- Footfall increased by 14.5% to 1.37 million visits during the quarter.
- Average realization per test increased by 8.8% to Rs 513.
- The wellness segment contributed around 14.5% of total revenue.
Transaction details
- The company signed a Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati, Assam, marking its entry into the North-East region.
- This acquisition expands Vijaya's geographical footprint beyond current markets, aiming to leverage integrated diagnostics expertise.
Order and execution details
- Commissioned 2 hubs and 7 spokes so far in FY2027 to expand network.
- Plans to commission an additional 3 hubs and 7 spokes in H2 FY2027 and 3 more hubs in Q1 FY2028.
Strategic context
- Focus on strengthening presence in existing and emerging markets like Pune and Tier-II cities such as Krishnanagar and Diamond Harbour.
- Expansion into North-East India reflects strategy to widen geographical reach and market presence.
Background and context
- Vijaya Diagnostic Centre operates over 165 diagnostic centres and 29 reference laboratories across 27 cities.
- The company provides integrated pathology and radiology services with a strong presence in six states including Telangana, Andhra Pradesh, Maharashtra, Karnataka, NCR, and West Bengal.
Highlights
- Revenue from operations increased by 26.7% year-over-year to Rs 2,553.9 million in Q2 FY2027.
- Total diagnostic tests rose 16.5% year-over-year to 4.98 million in Q2 FY2027.
- EBITDA margin improved by 355 basis points to 44.1% in Q2 FY2027.
- Commissioned 2 hubs and 7 spokes so far in FY2027 with plans for further expansion.
- Acquired Arya Wellness Centre in Guwahati, entering the North-East market.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
